Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression.
about
Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodiesA Compendium of Preparation and Application of Stem Cells in Parkinson's Disease: Current Status and Future ProspectsFunctional Evaluations of Genes Disrupted in Patients with Tourette's Disorder.Induced pluripotent stem cells for modeling neurological disordersEmerging Transcriptional Mechanisms in the Regulation of Epithelial to Mesenchymal Transition and Cellular Plasticity in the KidneyEpigenetic Research of Neurodegenerative Disorders Using Patient iPSC-Based ModelsInduced Pluripotent Stem Cells and Periodontal RegenerationMitochondria: A Therapeutic Target for Parkinson's Disease?Deconvoluting the complexity of autophagy and Parkinson's disease for potential therapeutic purposeUsing iPS Cells toward the Understanding of Parkinson's DiseasePatient-specific induced pluripotent stem cells in neurological disease modeling: the importance of nonhuman primate modelsDisease modeling and cell based therapy with iPSC: future therapeutic option with fast and safe applicationProgramming and Reprogramming Cellular Age in the Era of Induced PluripotencyNeurodegenerative diseases in a dish: the promise of iPSC technology in disease modeling and therapeutic discoveryiPSC-derived dopamine neurons reveal differences between monozygotic twins discordant for Parkinson's diseaseElevated α-synuclein caused by SNCA gene triplication impairs neuronal differentiation and maturation in Parkinson's patient-derived induced pluripotent stem cellsCRISPR-Mediated Epigenome EditingLRRK2 at the interface of autophagosomes, endosomes and lysosomesUtility of Induced Pluripotent Stem Cells for the Study and Treatment of Genetic Diseases: Focus on Childhood Neurological DisordersCell reprogramming and neuronal differentiation applied to neurodegenerative diseases: Focus on Parkinson's diseaseAlpha-synuclein and tau: teammates in neurodegeneration?Concise review: modeling multiple sclerosis with stem cell biological platforms: toward functional validation of cellular and molecular phenotypes in inflammation-induced neurodegenerationDistinct and Shared Determinants of Cardiomyocyte Contractility in Multi-Lineage Competent Ethnically Diverse Human iPSCs.Solving the puzzle of Parkinson's disease using induced pluripotent stem cells.ERKed by LRRK2: a cell biological perspective on hereditary and sporadic Parkinson's disease.Transcriptomic profiling of purified patient-derived dopamine neurons identifies convergent perturbations and therapeutics for Parkinson's disease.Recapitulating and Correcting Marfan Syndrome in a Cellular Model.Induced Pluripotent Stem Cells: Global Research Trends.Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome.ERK-mediated phosphorylation of TFAM downregulates mitochondrial transcription: implications for Parkinson's diseaseTargeted gene correction minimally impacts whole-genome mutational load in human-disease-specific induced pluripotent stem cell clones.Investigating human disease using stem cell models.Higher vulnerability and stress sensitivity of neuronal precursor cells carrying an alpha-synuclein gene triplicationInduced Pluripotent Stem Cells Meet Genome EditingGenome-Scale Networks Link Neurodegenerative Disease Genes to α-Synuclein through Specific Molecular Pathways.A Comparative View on Human Somatic Cell Sources for iPSC GenerationErythroid differentiation of human induced pluripotent stem cells is independent of donor cell type of origin.Stem cells on the brain: modeling neurodevelopmental and neurodegenerative diseases using human induced pluripotent stem cells.JNK inhibition of VMAT2 contributes to rotenone-induced oxidative stress and dopamine neuron death.Modeling human neurological disorders with induced pluripotent stem cells.
P2860
Q54807887-F634217C-C15C-4CED-A923-FD31E8A4F3D6Q54808175-C52136AC-B094-45B4-B09C-F72A6059994EQ54808177-DBC39728-07C3-4FDA-B112-EC04EE1931E3Q54814517-AF6F7ED8-5570-40B5-A133-F5780E9F960BQ54900926-A79CD1F7-A414-46C9-916D-CDD822C3548CQ54900927-66491B1D-D0C1-4237-A8AE-43A8565B4F3EQ54900928-C7525CB1-B01B-46AA-80FE-CE18921EDD39Q54900929-39EB3789-F5F5-4FB7-928B-2F26C82859F6Q54900930-35B480F9-4D33-4CC7-BFE5-2F6EFDB58F58Q54900987-F1C6C41B-46C3-4F8E-BD6C-974B432CEC33Q54900988-E298CBE8-3419-4A25-841D-A2E3E29C443DQ54900989-564E7547-A568-4F91-8728-EA4FB6653348Q54900990-CBB9AF5C-B81E-4081-B9B6-34DE6E125647Q54900991-0A22F640-584E-4CA2-BE2E-B0C79C87B265Q54900992-99105FC1-F203-42B9-9DE0-EBDCEF4C96D8
P1343
Q24318474-51018800-6265-4F1C-A816-66E53DBF9811Q26746033-916D80B9-F1CC-477C-8315-50D4A745EC7CQ26768144-AA849EF4-0EAC-4582-A288-9B87A4F66E1DQ26771402-E78DE5D0-585C-4ECC-9F82-585E0C6D60C0Q26771698-07A97B3F-3051-49CE-AAB1-BE222E0DA69EQ26772307-384506BE-26D3-46F0-BD5F-EB9CC0AC0E52Q26777488-713F51FC-F94F-4AAB-A4BB-52F579E4396BQ26784216-D9CE10B8-5354-4F96-8D5F-84DAC2ABAE51Q26785491-27D9D0F2-0073-4257-9F6B-68A6B1F6F259Q26799590-C2282678-BDBA-4D24-8EF5-CEFFF71EA2C3Q26825524-E1931ACC-2AA9-4E89-A887-01C0034DA9CDQ26866409-B03A731F-0BD6-477D-B6C7-EBAA3734A515Q27008903-52BB69A7-1CFF-41B5-A492-BC38B7E945F4Q27025493-8BF118E2-2723-4B73-A81A-5D6A3B49FB66Q27321433-F3A4FFEC-F047-43DD-9D0C-D2048D61594DQ27329722-B871EB1A-1863-42E0-97EA-C5B205CA4F14Q28075872-810B78A8-6310-4063-99DD-9A8DDEAEE200Q28078248-A31D519D-1449-485D-9A14-005730C68265Q28080219-4942C48D-36DD-40D5-880E-E69004B6202AQ28080770-D4DCB050-AD03-4B90-BA06-93FEC5EFB3B8Q28250508-E55535BC-1C07-47C5-9A7C-E95D4FB1D747Q28649438-CACB8E69-306A-4122-AAC5-C4C6EFEE8C2EQ30830783-04CD0FCD-1476-49CD-8C95-53F6E4FEF432Q33358637-A9DB88B6-6582-4B7C-B01A-5C4B03168031Q33593798-0C58E889-EC58-4602-935D-A23911E80C17Q33614776-DDC8F330-3C18-4ADA-9AF6-C09530B7CE47Q33717760-FB6A88C6-BEB1-4ED4-950E-960AB4E7068AQ33914515-1B5FB5A0-2161-48D6-9AEE-1A9DA936A109Q34038853-8EC349E8-4EB3-4777-8569-6FF3F25F6543Q34051280-9065EBC0-732F-463F-9FB3-59BC90632EA6Q34088395-81CBC6FB-50E1-4ECD-9F11-5EA0F43FA7BBQ34431170-0E4FA246-21DD-4470-BB93-7F53E8B700AAQ34497765-BDEAAD2D-6267-4E42-8B9B-9F75648E837DQ34525438-9FA9414A-9C1F-4344-9ED1-02F9D7AE74BAQ34550197-FB8542C3-C96F-44CB-9E9B-C62B43B07CC9Q34560769-B72DF75B-DB11-427D-A658-42F4D17D09ACQ34797997-D827F358-7DD6-4538-AA34-F1A50EC2AD4EQ34845881-0F2289EB-7F75-4198-B02E-89EEF2B6097BQ35019852-B207A70B-B71F-46E2-9871-2A32D281BA1AQ35056065-6FC1196F-80AE-44A1-A607-702217FD4466
P2860
Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Genetic correction of a LRRK2 ...... nt changes in gene expression.
@en
Genetic correction of a LRRK2 ...... nt changes in gene expression.
@nl
type
label
Genetic correction of a LRRK2 ...... nt changes in gene expression.
@en
Genetic correction of a LRRK2 ...... nt changes in gene expression.
@nl
prefLabel
Genetic correction of a LRRK2 ...... nt changes in gene expression.
@en
Genetic correction of a LRRK2 ...... nt changes in gene expression.
@nl
P2093
P4510
P50
P1433
P1476
Genetic correction of a LRRK2 ...... nt changes in gene expression.
@en
P2093
Ashutosh Dhingra
Benjamin Schmid
Cora S Thiel
David C Schöndorf
Guangming Wu
Gunnar Hargus
Heiko Müller
Jürgen Klingauf
Kathrin Brockmann
Lena F Burbulla
P304
P356
10.1016/J.STEM.2013.01.008
P407
P577
2013-03-01T00:00:00Z